Atonalp, a company advancing clinical diagnostics, life science research, and semiconductor and industrial process control through digital molecular profiling, is pleased to announce that Dr. James Rossman has agreed to join the Company's Board of Directors as an independent director. Dr. Rothman will bring his expertise to inform and advance the Company's roadmap for next-generation molecular sensing and diagnostic products.

Dr. ‍Rothman is currently Sterling Professor and Chair of Cell Biology at Yale University School of Medicine; prior to joining the Yale faculty in 2008, he was Chief Scientist at GE Healthcare and its predecessor, Amersham Corporation. Dr. Rothman also served as an advisor to top research management at Genentech, Merck & Co., Johnson & Johnson, GlaxoSmithKline, and Eli Lilly. Previously, he was a professor at Stanford University, Princeton University, Columbia University, and Memorial Sloan-Kettering Cancer Center, where he also served as vice chairman of the Sloan-Kettering Institute. Dr. Rothman received the Nobel Prize in Physiology or Medicine in 2013 and the Albert Lasker Basic Medical Research Award in 2002 for his work showing that small bag-like structures (called vesicles) help transport substances in the body. This work provided a conceptual framework for understanding such diverse and important processes as the release of insulin into the bloodstream, communication between nerve cells in the brain, and the entry of viruses into cells.

Dr. ‍Rothman's current research interests include the biophysics and regulation of membrane fusion in exocytosis, dynamics of the Golgi apparatus through super-resolution, and the use of bioinspired design in nanotechnology. He is a member of the National Academy of Sciences and the National Academy of Medicine.

‍"We are honored to have such a distinguished scientist join our company," said Prakash Murthy, founder and CEO of Atonalp. Dr. Rothman will be an invaluable resource in helping us achieve our mission to unlock molecular insights that will accelerate human progress."

Dr. Rothman said, "I am delighted to be working with Atonalp, as I am deeply impressed with their unique multi-laser optical spectroscopy and mass spectrometry technology platform. I envision a wide range of applications in the life sciences and look forward to working with the team to bring our vision to life," said Dr. Rothman.

About Atonarp
Atonarp advances clinical diagnostics, life science research, semiconductor and industrial process control through digital molecular profiling. Our ASTON and ATON platforms utilize innovative spectrometry and advanced analytical technologies to generate actionable results in real-time. Our platforms are applicable to a variety of applications across multiple industries. In-situ sensitive and fast molecular measurements in advanced manufacturing processes mean increased throughput, improved efficiency, and reduced waste. Our quantitative multiplex chemistry-free diagnostic tests enable point-of-care disease diagnosis and monitoring, improving outcomes and patient satisfaction at a lower cost.

‍

Contact Us
Carrie Mulherin Vice President of Marketing
Carrie.Mulherin@Atonarp.com